Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Capital Expenditures (2019 - 2023)

Alx Oncology Holdings' Capital Expenditures history spans 5 years, with the latest figure at $148000.0 for Q4 2023.

  • For Q4 2023, Capital Expenditures fell 73.14% year-over-year to $148000.0; the TTM value through Dec 2023 reached $1.3 million, down 10.72%, while the annual FY2025 figure was $212000.0, 52.57% down from the prior year.
  • Capital Expenditures for Q4 2023 was $148000.0 at Alx Oncology Holdings, up from -$1.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.9 million in Q2 2020 and bottomed at -$1.9 million in Q3 2020.
  • The 5-year median for Capital Expenditures is $202500.0 (2022), against an average of $208500.0.
  • The largest annual shift saw Capital Expenditures soared 8314.29% in 2022 before it plummeted 4443.33% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at -$62000.0 in 2019, then soared by 117.74% to $11000.0 in 2020, then skyrocketed by 2272.73% to $261000.0 in 2021, then soared by 111.11% to $551000.0 in 2022, then plummeted by 73.14% to $148000.0 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Capital Expenditures are $148000.0 (Q4 2023), -$1.3 million (Q3 2023), and $1.7 million (Q2 2023).